Norepinephrine Bitartrate In 5% Dextrose (norepinephrine bitartrate)

Frequently asked

Common questions about Norepinephrine Bitartrate In 5% Dextrose's patent landscape

When will generics enter the market for Norepinephrine Bitartrate In 5% Dextrose?

Nominal patent expiry shows the cliff window: Mar 6, 2040 (when the foundational composition patent expires) to Mar 7, 2041 (when the last US OB patent falls). In practice, generics typically enter mid-window via negotiated settlement — Hatch-Waxman settlements often produce delayed-entry agreements between the brand and the first ANDA filer, typically trading a 180-day exclusivity for an entry date months to years past the patent. Exact entry depends on patent challenges, design-around feasibility, and settlement negotiations.

What's the difference between "cliff opens" and "cliff closes"?

Cliff opens (Mar 6, 2040) marks Norepinephrine Bitartrate In 5% Dextrose's foundational composition patent expiry — the earliest theoretical date for generic entry. Cliff closes (Mar 7, 2041) is when the last US patent in the thicket finally falls — after which the market has no patent-based barriers. The gap between these two dates is the lifecycle-extension window: secondary patents (formulations, methods of use, manufacturing) that can block generics even after the composition patent has expired.

Why is Norepinephrine Bitartrate In 5% Dextrose in the Orange Book?

Norepinephrine Bitartrate In 5% Dextrose is regulated via the FDA 505(b) NDA pathway for small-molecule drugs and listed in the FDA Orange Book (small molecules). Small-molecule NDA holders must list approved-use patents in the Orange Book under Hatch-Waxman. The patents shown here come directly from FDA Orange Book listings.

What's a patent family and why does it matter?

A patent family is a group of patent applications and grants worldwide that share the same priority filing (the earliest invention disclosure). One US patent often expands to 20–40+ filings across different jurisdictions — each grant in a different country protecting the same underlying invention. Norepinephrine Bitartrate In 5% Dextrose has 1 family that resolve to 10 international documents across 4 countries. Families matter because generic entry requires clearing patent barriers in each market separately — a US generic launch is independent of EU or Japan launches.

How were these Norepinephrine Bitartrate In 5% Dextrose patents identified?

Norepinephrine Bitartrate In 5% Dextrose's 2 US patents come directly from the FDA Orange Book, which small-molecule NDA holders are required to list under Hatch-Waxman. We then expand each Orange Book patent to its full international family using the BigQuery patent family graph (priority date + global jurisdictions). The US patent list is FDA-authoritative.

What does the "Multiplier" stat mean?

The multiplier shows how many international patent documents exist for every US patent in Norepinephrine Bitartrate In 5% Dextrose's thicket — calculated as 10 international documents ÷ 2 US patents = 5×. A high multiplier (>10×) indicates an aggressive global filing strategy — the sponsor has filed in many countries to maximize geographic protection. A low multiplier suggests the patent estate is US-centric, with limited international protection.